Ann C. Miller
Dr. Miller was appointed as a director of Puma Biotechnology on November 12, 2019. Since March 2019, she has served as a member of the Board of Directors of Inovio Pharmaceuticals, Inc., a publicly held biotechnology company focused on the discovery, development, and commercialization of its synthetic DNA technology targeted against cancers and infectious diseases. Since October 2020, she has served as a member of the Board of Directors of Allena Pharmaceuticals, a publicly held biotechnology company focused on developing a pipeline of first-in-class, oral, non-absorbed enzyme therapeutic candidates to treat patients with rare and severe metabolic disorders that affect the kidney.
Prior to that, Dr. Miller worked at Sanofi S.A. from 2012 until her retirement in September 2018, serving as Vice President of Marketing and Vice President of Global Marketing, Oncology Division. From 2009 to 2011, Dr. Miller was at Eisai Co., Ltd and served as Senior Vice President of Pharmaceutical Services and Senior Vice President of the Primary Care and Specialty Business unit. Dr. Miller previously served in management roles in Global and U.S. Marketing at Amgen Inc. over a period of six years and in positions of increasing responsibility at Merck & Co., Inc. over a period of 16 years.
Dr. Miller received an M.D. from the Duke University School of Medicine and a B.A. in
chemistry with honors from Duke University. She was selected as a director because of her broad commercial background in the biopharmaceutical industry and her clinical training and experience.
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024